Nuzyra received FDA approval for the treatment of adults with community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI) [1]. The drug was approved on October 4, 2018 [2].
What is Nuzyra used for?
Nuzyra is indicated for adults with CABP and ABSSSI. It is an intravenous (IV) and oral formulation of omadacycline, a tetracycline-class drug [1][2].
How does Nuzyra work?
Omadacycline works by inhibiting bacterial protein synthesis. It binds to the 30S ribosomal subunit of susceptible bacteria, preventing the incorporation of amino acids into growing peptide chains [1].
When does Nuzyra's patent protection end?
Information on Nuzyra's specific patent expiration dates is not publicly detailed here, but patent information for drugs is tracked by resources like DrugPatentWatch.com [3].
What are the key clinical trial results for Nuzyra?
The FDA approval was based on two Phase 3 clinical trials: the pneumonia trial (NOVA) and the skin infection trial (SOLAR) [1]. In the NOVA trial, Nuzyra met its primary efficacy endpoint, demonstrating non-inferiority to an active comparator in the treatment of CABP [4]. The SOLAR trial also met its primary efficacy endpoint, showing non-inferiority to an active comparator in the treatment of ABSSSI [1].
What are the potential side effects of Nuzyra?
Common side effects observed in clinical trials include nausea, vomiting, diarrhea, dizziness, insomnia, headache, and elevated liver enzymes [1].
How does Nuzyra compare to other antibiotics?
Nuzyra is a tetracycline-class antibiotic with a broad spectrum of activity, including against Gram-positive bacteria like methicillin-resistant Staphylococcus aureus (MRSA) and Gram-negative bacteria [1]. Its efficacy and safety profile are evaluated against other approved antibiotics for CABP and ABSSSI in clinical practice.
What is the dosage and administration of Nuzyra?
Nuzyra is administered intravenously or orally. The standard dosage for both CABP and ABSSSI is 300 mg every 24 hours for 7 to 14 days, depending on the infection type [1].
What is the development history of Nuzyra?
Nuzyra was developed by Paratek Pharmaceuticals. It was approved by the FDA in 2018 [2][5].
Who manufactures Nuzyra?
Nuzyra is manufactured by Paratek Pharmaceuticals [5].
Are there any warnings or precautions for Nuzyra use?
Nuzyra carries warnings regarding potential adverse effects such as hepatotoxicity, QT prolongation, and photosensitivity [1]. It is also contraindicated in patients with known hypersensitivity to omadacycline or other tetracyclines [1].
What is the cost of Nuzyra?
Pricing information for Nuzyra is typically available through pharmaceutical distributors and formulary listings, and can vary based on insurance coverage and healthcare setting [6].
Are there any alternative treatments for CABP and ABSSSI?
Yes, there are several alternative antibiotic treatments available for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections, with the choice often depending on the specific pathogen, patient factors, and local resistance patterns [7].
What is the regulatory status of Nuzyra in other regions?
Following its FDA approval, Nuzyra has also been reviewed and approved by other regulatory agencies in different regions [1].
What are the patient concerns regarding Nuzyra?
Patient concerns may include understanding the potential side effects, the duration of treatment, and the administration route (IV vs. oral) [8]. Information from patient support programs and healthcare providers addresses these concerns.
What is the mechanism of action against resistant bacteria?
Nuzyra, as a tetracycline derivative, targets bacterial ribosomes. Its effectiveness against resistant strains stems from its ability to overcome common resistance mechanisms found in bacteria, such as efflux pumps [1].
Can Nuzyra be used in pediatric populations?
The FDA approval for Nuzyra is for adult patients. Use in pediatric populations would require separate clinical studies and regulatory review [1].
Sources:
1. FDA Approval Letter and Labeling Information for Nuzyra.
2. U.S. Food & Drug Administration. (2018). FDA Drug Approvals and Databases.
3. DrugPatentWatch.com. (n.d.). https://drugpatentwatch.com/
4. Paratek Pharmaceuticals Press Release. (2018).
5. Paratek Pharmaceuticals Website. (n.d.).
6. Pharmacy and Healthcare Provider Resources.
7. Infectious Diseases Society of America (IDSA) Guidelines.
8. Patient Information Leaflets and Physician Prescribing Information.